IL-2 Family · · · Mechanisms of · · ·

项目来源

美国卫生和人类服务部基金(HHS)

项目主持人

未公开

项目受资助机构

NATIONAL HEART, · · · INSTITUTE

项目编号

1ZIAHL005402-27

立项年度

2018

立项时间

未公开

项目级别

国家级

研究期限

未知 / 未知

受资助金额

2188622.00美元

学科

Biotechnology; Cancer; · · · Human Genome; · ·

学科代码

未公开

基金类别

INTRAMURAL RESEARCH

关键词

未公开

参与者

LEONARD, WARREN ·

参与机构

NATIONAL HEART, · · · INSTITUTE

项目标书摘要:The IL-2 · · · cytokine/cytokine receptor · · · studied to · · · cell immune · · · and pathologic · · · activation, the · · · of the · · · by IL-2, · · · receptors, and · · · of their · · · is highly · · · infected with · · · of adult · · · (ATL). There · · · of the · · · and gc, · · · IL-2Rb being · · · level of · · · shared by · · · IL-9, IL-15, · · · and is · · · We study · · · by these · · · proteins and · · · which they · · · Given our · · · Stat5a or · · · develop tumors, · · · being implicated · · · and elevated · · · of human · · · relevance for · · · pathological states. · · · mice with · · · expression have · · · helper cell · · · for normal · · · Th1 differentiation · · · defense to · · · intracelllular pathogens, · · · in allergic · · · differentiation vital · · · including psoriasis · · · disease. We · · · IL-2 is · · · differentiation and · · · IL-4 receptor · · · STAT5-dependent manner · · · of cells · · · Moreover, using · · · coupled to · · · analysis, we · · · regulation of · · · STAT5A and · · · these findings · · · IL-2 via · · · which is · · · differentiation. We · · · IL-2 via · · · T-bet. Interestingly, · · · expression of · · · helping to · · · of Th17 · · · had reported · · · of IL-2 · · · with a · · · IL-2 on · · · its induction · · · to the · · · that IL-2 · · · opposing actions · · · based on · · · by IL-21 · · · IL-2. In · · · we have · · · of new · · · a computational · · · Th differentiation. · · · with Dr. · · · (Stanford), generating · · · which represent · · · agonists for · · · cytokine. These · · · function as · · · retaining high · · · inhibiting binding · · · but their · · · was weakened, · · · We previously · · · variant, denoted · · · survival in · · · graft-versus-host disease · · · proliferation of · · · cell leukemia · · · This receptor-clamping · · · a general · · · applications to · · · cytokines as · · · past year, · · · study of · · · additionally have · · · partial agonists. · · · actions on · · · and we · · · it also · · · conventional dendritic · · · STAT3 and · · · this is · · · colony-stimulating factor · · · had revealed · · · between GM-CSF-induced · · · STAT3, and · · · roles for · · · in IL-21 · · · cells. Previously, · · · that IL-21 · · · the Prdm1 · · · BLIMP1 via · · · that depends · · · IRF4 and · · · in contrast · · · ability to · · · in B · · · via Ets-IRF · · · IRF4 cooperates · · · proteins to · · · AP1-IRF composite · · · T cells, · · · in B · · · AICEs and · · · and we · · · the expression · · · a protective · · · Pylori infection · · · (NIAID) and · · · study by · · · showing that · · · together with · · · control effector · · · differentiation. In · · · had studied · · · of Egr1 · · · elucidated some · · · Egr1, demonstrating · · · factor has · · · effect on · · · required for · · · the BALB/c · · · on the · · · we studied · · · of STAT5 · · · by generating · · · forms of · · · that could · · · not tetramers · · · intricate modeling · · · structure of · · · the current · · · the basis · · · cell development · · · knockin mice, · · · role for · · · the survival · · · We also · · · of tetramers · · · types as · · · key studies, · · · globally characterized · · · regulated by · · · IL-21-activated STAT3 · · · to highly · · · we found · · · gene contains · · · ranked STAT5-dependent · · · ChIA-PET methodology, · · · long-distance chromatin · · · using CRISPR-Cas9 · · · functionally dissected · · · this super-enhancer, · · · insights into · · · of the · · · and super-enhancers · · · collaborative studies · · · (Stanford), we · · · haplotype-based computational · · · identify genes · · · differentiation. Overall, · · · our understanding · · · which gc · · · gene expression · · · and are · · · and pathological · · · including in · ·

  • 排序方式:
  • 2
  • /
  • 3.Tr···cr···io···ac···s ···8a···PU···re···qu···d ··· f···ic···r ···el···ev···pm··· a···BC···dr···n ···mi··· c···er···sp···es

    • 关键词:
    • SEQUENCE BINDING-PROTEIN; MARGINAL-ZONE; POSITIVE SELECTION; CUTTING EDGE; B1B CELLS; EXPRESSION; LINEAGE; ICSBP; BCL6; LYMPHOCYTE
    • Wa··· H···sh···;J···, ···et···i,···ng···n,···an···n;··· J···su···i,···en···g;···, ···ny···;S··· J···an···ak··· T···mi···gh···fa···Zo···h;···as···Sa···;K···lc···, ···xa···r ···Bo···nd···il···;N···, ···ph···L.···on···, ···re···.;···se···er···t ··· I··
    • 《PR···ED···S ···TH···AT···AL···AD··· O···CI···ES··· T···UN···D ···TE···F ···RI··》
    • 2019年
    • 116卷
    • 19期
    • 期刊

    Th···RF···d ··· f···li···of···an···ip···n ···to···re···at···he···pr···io···f ···an···of···ne···nv···ed··· i···ne···ll···ve···me···an···un···on···ow···r,···e ···er···nd··· o···he···le···ar···ch···sm···f ···h ···il···em··· h···be···li···ed···e ···th··· r···nd···y ··· b···d ···ec···on···ti··· l···ag···of···ll···He··· w···ep··· t··· d···le···le···n ···fl···d ···8 ··· S··· (···od··· P···) ···Mb···re···es···at···DK···ic···in···e ···el···in···e ···ul··· i···ev··· d···ct···n ··· d···lo···nt··· f···ic···r ··· g···in···ce···r ···) ···el··· C···s-···tc···ec···in···on···d ···ib··· a···ni···ma···at··· w··· a··· c···ro···ed··· D···mi··· R···se···se···nc···) ··· C···-s···an···se···ev···ed···st···t ···8 ··· P··· t···et···ne···n ···li···ar···d ···iv···d ···el··· D···B ···ls···d ···in···ed···pr···io···f ···ge···en···vi··· f···ma···ai···g ···li···ar···ce···id···it···nd··· d···lo···nt···or···er···ur···nd···s ···ea···ha···xp···si···of···ce···ly···om···ro···n ···BC···, ···ch··· c···ic···fo···ev···pm··· o···er···al···nt···B ···ls···s ···en···t ···IR···an···U.···n ···o,···ov···ng···me···ni···fo···he···it···l ···e ··· I··· a···PU···in···e ···el···en···f ···B ···ls·

    ...
  • 4.IL···/t··· I···te···ro···nt···la···eg···te···eu···ph···de···de···in···e ···un···es···se···o ···ph···co···s ···eu·

    • 关键词:
    • COMMON GAMMA-CHAIN; GRANZYME-B; HOST-DEFENSE; CELL-DIFFERENTIATION; FOLLICULAR-HELPER; INTERLEUKIN-21; STAT3; TRANSCRIPTION; EXPRESSION; GENERATION
    • Sp···ki···os···e;···t,···in···;L···Pe···Ve···er···, ···ro···un···Su···;K···mi··· M···d;··· J···su···u,···-X···re···n,···ex···ra···;H···an···St···en···;M···hy···hi··· M···eo···d,···rr···J.
    • 《EL···》
    • 2019年
    • 8卷
    • 期刊

    Me···ci···n-···is···t ···ph···co···s ···eu···MR··· i··· m···r ···pi···- ··· c···un···ac···re···at···en···ut···e ···ha···ms···de···in···os···ef···e ···MR···re···n ···rl···nd···to··· H···, ···in···ti···ed···e ···e ···IL··· i···hi···ro···s.···en···mi···te··· i···at···he···y ···o ···d-···e ···e,···-2···nd···d ···nz···s ··· a···en··· c···ra··· o···ul···ar···RS···ut···t ···n ···tr···il···er···ep···ed··· a···an···e ···nh···to···as···de···Co···sp···in···, ···21···du··· M··· k···in···y ···an···ri···ra···lo···ne···op···s.···ex···te···, ···ev··· b···l ···A ···ar···e ··· a··· e···nc···wh···IL··· s···al··· w···bl···ed···ot···n ···1r··· m··· a···in···ld···pe···ce···je···d ···h ···21···c ···io···ro···n.···is···rr···te···it···nc···se···yp··· i···rf···n ··· a···FN···la··· g··· s···at···, ··· i···ed···ti···NA···tr···me···di···is··· M··· c···ra··· i···he···an···ls···or···er···e ···nd···at···N ···a ···uc···gr···ym··· a···pr···te···RS···le···nc···n ···ra···me···de···de···fa···on···he···re···ts···ve···an···te···ay···tw··· I···1 ··· t··· I···N ···th···nn··· i···ne···sp···e ···MR···

    ...
  • 5.Th···am···c)···il···f ···ok···s:···ic···ol··· t···he···eu··· R···fi···io··

    • 关键词:
    • SEVERE COMBINED IMMUNODEFICIENCY; REGULATORY T-CELLS; HUMAN INTERLEUKIN-2 RECEPTOR; LOW-DOSE INTERLEUKIN-2; INNATE LYMPHOID-CELLS; BETA-CHAIN GENE; IL-2 RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTOR; NATURAL-KILLER
    • Le···rd···ar··· J···in···ia···in···Sh··· J··· J·
    • 《IM···IT·》
    • 2019年
    • 50卷
    • 4期
    • 期刊

    Th···om··· c···ki···re···to···am···ch···, ···ma···, ···a ···po···t ···th···ec···or···or···te···uk···2 ···-2···IL··· I···, ···9,···-1···an···L-··· M···ti···of···e ··· e···di···ga···(c···es···s ···X-···ke···ev··· c···in···im···od···ci···y ···hu···s,···d ···ga···(c···am··· c···ki··· c···ec···el···eg···te···ve···me··· p···if···ti··· s···iv··· a···di···re···at··· o···mm··· c···s.···re···e ···ie···he···si···io···y ···th··· c···ki···, ···hl···ti···me···ni··· o···ig···in···nd···ne···gu···io···ha···av···ro···ed···si···s ··· i···no···ic···cy···ut···mu···y,···le···c ···ea···, ··· c···er···or···er···e ···cu···ho···tu···s ···th···fa···y ···mu···ed···e ···el···en···f ···3 ···ib···rs···d ···se···an···er···w ···cu···nt···ra···ie···ar···in···he···pa···ay···n ··· c···ic···nc···in···ov···an···od···, ···ag···st···an···ar···l ···ni···. ··· d···rs···ol···of···es···yt···ne···n ···an···im···e ···ls···ve···po···nt···er···ut···im···ca··· s·

    ...
  • 7.Fi···Tu···g ···ok··· S···al·

    • 关键词:
    • GENOME-WIDE ASSOCIATION; SEVERE COMBINED IMMUNODEFICIENCY; LOW-DOSE INTERLEUKIN-2; REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; DNA-BINDING ACTIVITY; GENE-THERAPY; RECEPTOR-ALPHA; MITOCHONDRIAL STAT3; SUSCEPTIBILITY LOCI
    • Li···Ji···Xi···eo···d,···rr···J.
    • 《AN···L ···IE···F ···UN···GY···OL···, ···9》
    • 2019年
    • 会议

    Cy···in···ar···ec···ed··· o···rw··· r···as···po···ep···e ···to···th···ex··· a···cr··· a···or···ra···ne···ti···, ···h ···t ···ok···s ···in···n ··· i···ne···d/···he···op···ti···ys···. ···y ··· t···ca··· p···ot···ic···on···ll··· d···lo···nt···el···ro···, ···vi···, ···/o···if···en···ti··· C···es···di···y,···to···es···e ···ni···ly···po···nt···nd···gm···in···r ···en···in···yt···ne···gn··· c···ha···de···er···s ···th···pe···c ···ec··· B···de···hy···lo···al···ne···ni···of···to···e ···na··· a···ri···th···at··· o···ot···y ···th···ig··· c···be···po···nt··· p···op···io···ic···re···ns···an···an···so···ov··· n···l ···ra···ti···pp···ch··· H···, ···gi···an···er···w ···cy···in··· t···r ···na···g ··· a···on···an···he···ys···og···l ···ha···ms···d ···rm···lo··· s···te···s ···fi···tu···th··· a···on···In···rt···la···th···if···en···l ···li···io···f ···T ···te··· b··· s···le···to···e ···by···ff···nt···to···es···d ···T ···er···ti···ve···s ···ra···iz···on···e ···si···gi··· m···an···s ···fi···tu···g,···er··· a···cy···in···nd···ti···ok··· r···pt···an···od··· a···cy···in···wi···al···ed···ti···ie···in···di···cy···in···up···go···ts···ar···l ···ni···, ··· a···go···ts···ep···en···ew···ys··· f···-t···ng···to···e ···na···

    ...
  • 8.Ch···at···Ac···si···it···nd···te···ti··· i···he···an···ip···na···eg···ti···of···Ce···

    • 关键词:
    • INTERLEUKIN-2-RECEPTOR GAMMA-CHAIN; HUMAN GENOME; FUNCTIONAL COMPONENT; TH2 DIFFERENTIATION; SUPER-ENHANCERS; GENE-EXPRESSION; STAT5; IDENTITY; ACTIVATION; RECEPTOR
    • Li···en···eo···d,···rr···J.
    • 《FR···IE···IN···MU···OG·》
    • 2018年
    • 9卷
    • 期刊

    Du···g ···el···if···en···ti···an···ct···ti··· s···if···st···li···nd···ne···rk··· t···sc···ti···fa···rs···Fs···re···vo···d ···or···st···in···hr···ti···cc···ib···ty···st···is···g ···an···-p···ot···in···ac···ns···nd···gu···in···en···xp···si··· O··· t···pa···fe···ea··· t···e ···e ···n ··· i···gh···in···ho···hr···ti···nt···ct···s ···rd···te···ff···nt···io···ur··· T···ll···ve···me···an···ow···gu···or···le···ts···e ···gr···ed··· a···w ···el···to···ff···nt···ly···sp··· t···is···ct···im···. ···th···re···w,··· d···us···ec··· a···nc···re···ed··· t···ro··· o···Fs··· e···bl···in···he···gu···or···hr···ti···an···ap···th···or···st···e ···el···ev···pm··· a···di···re···at···. ···pa···cu···, ···fo··· o···he···le··· T···(e···, ···-1···CL···, ···1,···AT···ST···, ···1,···d ···4)··· m···at··· c···ma··· a···ss···li···an···nt···ct···s ··· i···eg···ti···ge···ex···ss··· i··· c···s,···cl···ng···ne···pr···io···ha···s ···en···t ···IL···an···L-··· F···he···re···e ···cu···th···ta···of···ow···ge··· e···nc···pr···te···nt···ct···s ··· h···au···mm··· d···as···is···ar···ts···n ···li···d ···mo···ul···fu···io···of···ta···e ···ge···en···

    ...
  • 9.Bi···gy···d ···ul···on··· I···:f··· m···cu··· m···an···s ···hu··· t···ap·

    • 关键词:
    • SEVERE COMBINED IMMUNODEFICIENCY; RECEPTOR BETA-CHAIN; INTERLEUKIN-2-RECEPTOR GAMMA-CHAIN; T-CELL DIFFERENTIATION; LOW-DOSE INTERLEUKIN-2; ALPHA-CHAIN; IN-VIVO; TRANSCRIPTION FACTOR; CHROMATIN INTERACTIONS; SELECTIVE STIMULATION
    • Sp···ki···os···e;··· P···;L···ar···Wa···n ··
    • 《NA···E ···IE···IM···OL···》
    • 2018年
    • 18卷
    • 10期
    • 期刊

    IL···wa···ir···id···if··· a··· g···th···ct···ca···le··· d···in···he···pa···on··· a···va··· h···n ···el···op···ti···. ···th···or···ha···0 ···rs···nc···ts···sc···ry··· t···en···s ···un···as···en···ar··· r···rd··· t···me···ni··· t··· r···la···th···xp···si···of···th···-2···d ··· c··· s···ac···ec···or···ts···ch···sm···f ···na···ng···d ··· r···e ···bi···gi··· a···on···Mo···re···tl···th···ec···is···by···ic···L-···eg···te···D4··· T···ll···ff···nt···io···nd···nc···n ···e ···n ···ci···ed···L-···ls···eg···te···he···fe···r ··· m···ry···sp···es··· C···+)···ce···, ··· t···lo···of···-2··· r···on···en··· t···L-···t ···st··· p··· e···ai···th···xh···te···he···yp···ha···cc··· d···ng···ro··· v···l ···ec···ns···d ···tu···r ···po···s.···es···as···me···ni···c ···di···ha···le···o ··· t···ap···ic···il··· t···an···la···th···ct··· o···L-···n ···ul···ry···(T···g)···ll···or···e ···at···t ···au···mm··· d···as···nd··· C···+)···ce··· f···im···ot···ap···f ···ce···IL···ca···av···it··· p···ti···or···le···io···ef···ts···nd··· d···us···er···ec··· i···s ··· a···oa···s ··· m···pu···in···he···ti··· a···ov···ll···t ···ec···of···-2··· d···as···et···gs···nc···in···an···.

    ...
  • 10.Th···om··· C···ki···Re···to···ha···Fa···y ···Cy···in··

    • 关键词:
    • REGULATORY T-CELLS; SEVERE COMBINED IMMUNODEFICIENCY; INTERLEUKIN-2-RECEPTOR GAMMA-CHAIN; DEFECTIVE LYMPHOID DEVELOPMENT; THYMIC STROMAL LYMPHOPOIETIN; FOLLICULAR-HELPER-CELLS; LOW-DOSE INTERLEUKIN-2; IL-2 RECEPTOR; BETA-CHAIN; TRANSCRIPTION FACTOR
    • Li···Ji···Xi···eo···d,···rr···J.
    • 《CO···SP···G ···BO···ER···CT···S ···BI···GY》
    • 2018年
    • 10卷
    • 9期
    • 期刊

    In···le···n ···)-···IL··· I···, ···9,···-1···an···L-···fo···a ···il···f ···ok···s ···ed··· t···r ···ri···th···om··· c···ki···re···to···am···ch··· (···ma···, ···ch···s ···gi···ly···sc···re···s ··· t···d ···ep··· c···on··· o···he···-2···ce···r,···-2···am··· T···IL··· g··· i···oc···d ···th··· c···mo···e ··· i···ut···d ···hu···s ···h ···in··· s···re···mb···d ···un···fi···nc···XS···).···e ···ad···of···e ···ec···in···CI···ou···no···e ···la···d ···el···y ···ec···in···-2···gn···ng···nd··· i···ow···ar···at···mm··· i··· s···ed···ce···r ···po···t ···th···ix···to···es···te···bo··· m···ng···CI··· d···as···f ···ec···e ···ok··· s···al···. ···us···na···(J··· 3···so···te···it···am···c,···d ···3-···ic···t ···D ···no···ie···SC··· f···in···th···se···d ···st···la···th···ev···pm··· o···AK···nh···to···as···mu···up···ss···s.···mm··· f···ly···to···es···ll···iv··· c···ro···ro···as···ts··· l···ho···e ···el···en···gr···h,···ff···nt···io···an···ur···al···nd···es···yt···ne···re···in···ll···mp···an···re···ed··· a···rg···an···ut···mu···di···se···nd···nc···as···ll··· i···no···ic···cy···n ···s ···ie···we···sc··· t···ac···ns··· t···e ···ok···s,···ei···ri···al···ol···ca···ol···an···ig···in···at···ys···oc···ng···in···on···K/···T ···gn···tr···du···s ··· a···va···s ···tr···cr···io···si···li··· a···ho···hi···nf···at··· i···ow···in···se···n ···ni··· t···ap···ic···fo···.

    ...
  • 排序方式:
  • 2
  • /